Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04458610 · ClinicalTrials.gov registry record · Phase 2

Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

A Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT04458610: Active Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, sponsored by M.D. Anderson Cancer Center.

NCT04458610 is a Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, above the 43-participant average among 7 other Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trials with a reported enrollment target (40% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04458610, a Phase 2 study of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. The study is being done to find out if zanubrutinib combined with rituximab can help control previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Conditions Studied

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

  • DRUG Zanubrutinib
  • BIOLOGICAL Rituximab

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2020-05-26
Est. Completion 2026-05-26
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04458610

The ClinicalTrials.gov registry entry for NCT04458610 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 43-participant average among 7 other Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma trials with a reported enrollment target (40% higher). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Zanubrutinib is the first listed.

NCT04458610 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04458610 about?

NCT04458610 is a clinical study titled "Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". This phase II trial studies how well zanubrutinib and rituximab work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma for which the patient has not received treatment in the past (previously untreated). Zanubrutinib may stop the growth of cancer cells by blocking ...

What is the current status of trial NCT04458610?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2020-05-26. Estimated completion is 2026-05-26.

What conditions does trial NCT04458610 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

What interventions are being tested in trial NCT04458610?

The interventions under investigation include: Zanubrutinib (DRUG), Rituximab (BIOLOGICAL).

Who is sponsoring clinical trial NCT04458610?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04458610 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.